The Role of Endothelial Progenitor Cells in Coronary Artery Disease: Basic Molecular Mechanisms and Its Clinical Potentials

Yudi Her Oktaviono, Suryo Ardi Hutomo, Kevin Luke

Abstract


BACKGROUND: Coronary artery disease (CAD) remains as the world number one cause of morbidity and mortality. Endothelial progenitor cells (EPCs) are known to be involved in vascular biology. Current review briefly summarizes the basics of EPCs and its clinical use in CAD.

CONTENT: EPCs were firstly isolated in 1997 and involved in neovascularization. Further evidence defined EPCs into two distinguishable groups, namely: myeloid angiogenic cells (MACs) and endothelial colony forming cells (ECFCs). Common cardiovascular drugs, statin, angiotensin-converting enzyme (ACE) inhibitor, and their combinations, showed beneficial effects on EPCs. Likewise, the incorporation of EPCs upon CAD intervention management had been recently studied. Intramyocardial EPCs implementation and anti-CD34 antibody-coated stents could provide a promising option for refractory symptoms in CAD.

SUMMARY: Association between EPCs and CAD is very dynamic and complex. EPCs could serve as both therapeutic target and agent in CAD patients. Subsequently, a universal definition of EPCs is needed for greater research in the future.

KEYWORDS: atherosclerosis, coronary artery disease, endothelial progenitor cells, neovascularization


Full Text:

PDF

References


Khan MA, Hashim MJ, Mustafa H, Baniyas MY, Al Suwaidi SKBM, AlKatheeri R, et al. Global epidemiology of ischemic heart disease: results from the global burden of disease study. Cureus. 2020; 12: e9349, CrossRef.

Asahara T, Murohara T, Sullivan A, Silver M, Van Der Zee R, Li T, et al. Isolation of putative progenitor endothelial cells for angiogenesis. Science. 1997; 275: 964-7, CrossRef.

Donahue M, Quintavalle C, Chiariello GA, Condorelli G, Briguori C. Endothelial progenitor cells in coronary artery disease. Biol Chem. 2013; 394: 1241-52, CrossRef.

Ribatti D. The discovery of endothelial progenitor cells. An historical review. Leuk Res. 2007; 31: 439-44, CrossRef.

Asahara T, Kawamoto A, Masuda H. Concise review: circulating endothelial progenitor cells for vascular medicine. Stem Cells. 2011; 29: 1650-5, CrossRef.

Chopra H, Hung MK, Kwong DL, Zhang CF, Pow EHN. Insights into endothelial progenitor cells: Origin, classification, potentials, and prospects. Stem Cells Int. 2018; 2018: 9847015, CrossRef.

Medina RJ, Barber CL, Sabatier F, Dignat-George F, Melero-Martin JM, Khosrotehrani K, et al. Endothelial progenitors : a consensus statement on nomenclature. Stem Cells Transl Med. 2017; 6: 1316-20, CrossRef.

Hur J, Yoon CH, Kim HS, Choi JH, Kang HJ, Hwang KK, et al. Characterization of two types of endothelial progenitor cells and their different contributions to neovasculogenesis. Arterioscler Thromb Vasc Biol. 2004; 24: 288-93, CrossRef.

Mukai N, Akahori T, Komaki M, Li Q, Kanayasu-Toyoda T, Ishii-Watabe A, et al. A comparison of the tube forming potentials of early and late endothelial progenitor cells. Exp Cell Res. 2008; 314: 430-40, CrossRef.

Cheng CC, Chang SJ, Chueh YN, Huang TS, Huang PH, Cheng SM, et al. Distinct angiogenesis roles and surface markers of early and late endothelial progenitor cells revealed by functional group analyses. BMC Genomics. 2013; 14: 182, CrossRef.

Nova-Lamperti E, Zúñiga F, Ormazábal V, Escudero C, Aguayo C. Vascular regeneration by endothelial progenitor cells in health and diseases. In: Microcirculation Revisited - From Molecules to Clinical Practice. London: InTech; 2016, CrossRef.

Sieveking DP, Buckle A, Celermajer DS, Ng MKC. Strikingly different angiogenic properties of endothelial progenitor cell subpopulations: insights from a novel human angiogenesis assay. J Am Coll Cardiol. 2008; 51: 660-8, CrossRef.

Shantsila E, Watson T, Tse HF, Lip GYH. New insights on endothelial progenitor cell subpopulations and their angiogenic properties. J Am Coll Cardiol. 2008; 51: 669-71, CrossRef.

Urbich C, Dimmeler S. Endothelial progenitor cells: Characterization and role in vascular biology. Circ Res. 2004; 95: 343-53, CrossRef.

Li DW, Liu ZQ, Wei J, Liu Y, Hu L Sen. Contribution of endothelial progenitor cells to neovascularization. Int J Mol Med. 2012; 30: 1000-6, CrossRef.

George AL, Bangalore-Prakash P, Rajoria S, Suriano R, Shanmugam A, Mittelman A, et al. Endothelial progenitor cell biology in disease and tissue regeneration. J Hematol Oncol. 2011; 4: 24, CrossRef.

Tilling L, Chowienczyk P, Clapp B. Progenitors in motion: Mechanisms of mobilization of endothelial progenitor cells. Br J Clin Pharmacol. 2009; 68: 484-92, CrossRef.

Hristov M, Erl W, Weber PC. Endothelial progenitor cells: mobilization, differentiation, and homing. Arterioscler Thromb Vasc Biol. 2003; 23: 1185-9, CrossRef.

Vasa M, Fichtlscherer S, Aicher A, Adler K, Urbich C, Martin H, et al. Number and migratory activity of circulating endothelial progenitor cells inversely correlate with risk factors for coronary artery disease. Circ Res. 2001; 89: E1-7, CrossRef.

Kunz GA, Liang G, Cuculoski F, Gregg D, Vata KC, Shaw LK, et al. Circulating endothelial progenitor cells predict coronary artery disease severity. Am Heart J. 2006; 152: 190-5, CrossRef.

Ma FX, Zhou B, Chen Z, Ren Q, Shi HL, Sawamura T, et al. Oxidized low density lipoprotein impairs endothelial progenitor cells by regulation of endothelial nitric oxide synthase. J Lipid Res. 2006; 47: 1227-37, CrossRef.

Cao Z, Tong X, Xia W, Chen L, Zhang X, Yu B, et al. CXCR7/p-ERK-Signaling is a novel target for therapeutic vasculogenesis in patients with coronary artery disease. PLoS One. 2016; 11: e0161255, CrossRef.

Zhou H, Tu Q, Zhang Y, Xie HQ, Shuai QY, Huang XC, et al. Shear stress improves the endothelial progenitor cell function via the CXCR7/ERK pathway axis in the coronary artery disease cases. BMC Cardiovasc Disord. 2020; 20: 403, CrossRef.

Huang S, He P, Xu D, Li J, Peng X, Tang Y. Acidic stress induces apoptosis and inhibits angiogenesis in human bone marrow-derived endothelial progenitor cells. Oncol Lett. 2017; 14: 5695-702, CrossRef.

Mena HA, Zubiry PR, Dizier B, Schattner M, Boisson-Vidal C, Negrotto S. Acidic preconditioning of endothelial colony-forming cells (ECFC) promote vasculogenesis under proinflammatory and high glucose conditions in vitro and in vivo. Stem Cell Res Ther. 2018; 9: 120, CrossRef.

Ouyang S, Li Y, Wu X, Wang Y, Liu F, Zhang J, et al. GPR4 signaling is essential for the promotion of acid-mediated angiogenic capacity of endothelial progenitor cells by activating STAT3/VEGFA pathway in patients with coronary artery disease. Stem Cell Res Ther. 2021; 12: 149, CrossRef.

Aragona CO, Imbalzano E, Mamone F, Cairo V, Lo Gullo A, D’Ascola A, et al. Endothelial progenitor cells for diagnosis and prognosis in cardiovascular disease. Stem Cells Int. 2016; 2016: 8043792, CrossRef.

Cheng Y, Jiang S, Hu R, Lv L. Potential mechanism for endothelial progenitor cell therapy in acute myocardial infarction: Activation of VEGF- PI3K/AkteNOS pathway. Ann Clin Lab Sci. 2013; 43: 395-401, PMID.

Jialal I, Devaraj S, Singh U, Huet BA. Decreased number and impaired functionality of endothelial progenitor cells in subjects with metabolic syndrome: Implications for increased cardiovascular risk. Atherosclerosis. 2010; 211: 297-302, CrossRef.

Huang PH, Chen JW, Lin SJ. Effects of cardiovascular risk factors on endothelial progenitor cell. Acta Cardiol Sin. 2014; 30: 375-81, PMID.

He Z, Chen Y, Hou C, He W, Chen P. Cigarette smoke extract changes expression of endothelial nitric oxide synthase (eNOS) and p16(INK4a) and is related to endothelial progenitor cell dysfunction. Med Sci Monit. 2017; 23: 3224-31, CrossRef.

Higashi Y, Kihara Y, Noma K. Endothelial dysfunction and hypertension in aging. Hypertens Res. 2012; 35: 1039-47, CrossRef.

Thum T, Hoeber S, Froese S, Klink I, Stichtenoth DO, Galuppo P, et al. Age-dependent impairment of endothelial progenitor cells is corrected by growth hormone mediated increase of insulin-like growth factor-1. Circ Res. 2007; 100: 434-43, CrossRef.

Xiao Q, Kiechi S, Patel S, Oberhollenzer F, Weger S, Mayr A, et al. Endothelial progenitor cells, cardiovascular risk factors, cytokine levels and atherosclerosis - Results from a large population-based study. PLoS One. 2007; 2: e975, CrossRef.

Briguori C, Testa U, Riccioni R, Colombo A, Petrucci E, Condorelli G, et al. Correlations between progression of coronary artery disease and circulating endothelial progenitor cells. FASEB J. 2010; 24: 1981-8, CrossRef.

Chiang CH, Leu HB, Huang PH, Chung FP, Huang CC, Wu TC, et al. SYNTAX Score is associated with circulating endothelial progenitor cells in patients with coronary artery disease. Acta Cardiol Sin. 2012; 28: 216-24.

Schmidt-Lucke C, Rössig L, Fichtlscherer S, Vasa M, Britten M, Kämper U, et al. Reduced number of circulating endothelial progenitor cells predicts future cardiovascular events: Proof of concept for the clinical importance of endogenous vascular repair. Circulation. 2005; 111: 2981-7, CrossRef.

Chiang KH, Cheng WL, Shih CM, Lin YW, Tsao NW, Kao YT, et al. Statins, HMG-CoA reductase inhibitors, improve neovascularization by increasing the expression density of CXCR4 in endothelial progenitor cells. PLoS One. 2015; 10: e0136405, CrossRef.

Vasa M, Fichtlscherer S, Adler K, Aicher A, Martin H, Zeiher AM, et al. Increase in circulating endothelial progenitor cells by statin therapy in patients with stable coronary artery disease. Circulation. 2001; 103: 2885-90, CrossRef.

Savitri TR, Oktaviono YH, Soemantri D. Effect of statins on endothelial progenitor cell (EPC) migration from peripheral blood of stable coronary artery disease patient. Indones J Cardiol. 2019; 40: 202-5, CrossRef.

Meuthia F, Oktaviono YH, Soemantri D. Effects of statins on endothelial progenitor cell proliferation from peripheral blood of stable coronary artery disease patient. Indones J Cardiol. 2017; 38: 6-12, CrossRef.

Dimmeler S, Aicher A, Vasa M, Mildner-rihm C, Adler K, Tiemann M, et al. Increase endothelial progenitor cells via the PI 3-kinase / Akt pathway. 2001; 108: 365-6.

Oktaviono YH, Farabi MJ Al, Meuthia F, Savitri TVR, Soemantri D. Rosuvastatin is superior compared to simvastatin and atorvastatin to induce endothelial progenitor cells migration. J Clin Diagnostic Res. 2019; 1077: 5-8, CrossRef.

Hibbert B, Ma X, Pourdjabbar A, Simard T, Rayner K, Sun J, et al. Pre-procedural atorvastatin mobilizes endothelial progenitor cells: clues to the salutary effects of statins on healing of stented human arteries. PLoS One. 2011; 6: e16413, CrossRef.

Eisen A, Leshem-Lev D, Yavin H, Orvin K, Mager A, Rechavia E, et al. Effect of high dose statin pretreatment on endothelial progenitor cells after percutaneous coronary intervention (HIPOCRATES Study). Cardiovasc Drugs Ther. 2015; 29: 129-35, CrossRef.

Silvestre JS, Bergaya S, Tamarat R, Duriez M, Boulanger CM, Levy BI. Proangiogenic effect of angiotensin-converting enzyme inhibition is mediated by the bradykinin B2 receptor pathway. Circ Res. 2001; 89: 678-83, CrossRef.

Min TQ, Zhu CJ, Xiang WX, Hui ZJ, Peng SY. Improvement in endothelial progenitor cells from peripheral blood by ramipril therapy in patients with stable coronary artery disease. Cardiovasc Drugs Ther. 2004; 18: 203-9, CrossRef.

Cacciatore F, Bruzzese G, Vitale DF, Liguori A, Nigris F De, Fiorito C, et al. Effects of ACE inhibition on circulating endothelial progenitor cells, vascular damage, and oxidative stress in hypertensive patients. Eur J Clin Pharmacol. 2011; 67: 877-83, CrossRef.

Oktaviono YH, Ahmad HA, Al Farabi MJ, Gandi P, Givani CL, Lumeno ISP, et al. Enhancement of EPC migration by high-dose lisinopril is superior compared to captopril and ramipril. F1000Research. 2021; 10: 15, CrossRef.

Oktaviono YH, Hutomo SA, Al-Farabi MJ, Chouw A, Sandra F. Human umbilical cord blood-mesenchymal stem cell-derived secretome in combination with atorvastatin enhances endothelial progenitor cells proliferation and migration. F1000Research. 2020; 9: 537, CrossRef.

Kondo T, Shintani S, Maeda K, Hayashi M, Inden Y, Numaguchi Y, et al. The number and function of circulating CD34+CD133+ progenitor cells decreased in stable coronary artery disease but not in acute myocardial infarction. Heart Asia. 2010; 2: 20-3, CrossRef.

Gallone G, Baldetti L, Tzanis G, Gramegna M, Latib A, Colombo A, et al. Refractory angina: from pathophysiology to new therapeutic nonpharmacological technologies. JACC Cardiovasc Interv. 2020; 13: 1-19, CrossRef.

Briceno N, Schuster A, Lumley M, Perera D. Ischaemic cardiomyopathy: Pathophysiology, assessment and the role of revascularisation. Heart. 2016; 102: 397-406, CrossRef.

Losordo DW, Schatz RA, White CJ, Udelson JE, Veereshwarayya V, Durgin M, et al. Intramyocardial transplantation of autologous CD34+ stem cells for intractable angina: A phase I/IIa double-blind, randomized controlled trial. Circulation. 2007; 115: 3165-72, CrossRef.

Soetisna TW, Sukmawan R, Setianto B, Mansyur M, Murni TW, Listiyaningsih E, et al. Combined transepicardial and transseptal implantation of autologous CD 133+ bone marrow cells during bypass grafting improves cardiac function in patients with low ejection fraction. J Card Surg. 2020; 35: 740-6, CrossRef.

Losordo DW, Henry TD, Davidson C, Sup Lee J, Costa MA, Bass T, et al. Intramyocardial, autologous CD34+ cell therapy for refractory angina. Circ Res. 2011; 109: 428-36, CrossRef.

Henry TD, Schaer GL, Traverse JH, Povsic TJ, Davidson C, Lee JS, et al. Autologous CD34+ cell therapy for refractory angina: 2-year outcomes from the ACT34-CMI study. Cell Transplant. 2016; 25: 1701-11,

Povsic T, Sietsema WK, Wang J, Takagi H, Kotynski C, Losordo DW. Design of a confirmatory pivotal study with intramyocardial GCSF-mobilized autologous CD34 cells (CLBS14) for the treatment of an orphan-sized population with no-option refractory disabling angina. Cytotherapy. 2020; 22: S64, CrossRef.

Povsic TJ, Henry TD, Traverse JH, Fortuin FD, Schaer GL, Kereiakes DJ, et al. The RENEW Trial: efficacy and safety of intramyocardial autologous CD34+ cell administration in patients with refractory angina. JACC Cardiovasc Interv. 2016; 9: 1576-85, CrossRef.

Sethi R, Lee CH. Endothelial progenitor cell capture stent: Safety and effectiveness. J Interv Cardiol. 2012; 25: 493-500, CrossRef.

Aoki J, Serruys PW, van Beusekom H, Ong AT, McFadden EP, Sianos G, et al. Endothelial progenitor cell capture by stents coated with antibody against CD34: the HEALING-FIM (Healthy Endothelial Accelerated Lining Inhibits Neointimal Growth-First In Man) Registry. J Am Coll Cardiol. 2005; 45: 1574-9, CrossRef.

Klomp M, Beijk MAM, de Winter RJ. GenousTM endothelial progenitor cell-capturing stent system: A novel stent technology. Expert Rev Med Devices. 2009; 6: 365-75, CrossRef.

Klomp M, Beijk MAM, Verouden NJW, Tijssen JGP, de Winter RJ. Design and rationale of the TRI-stent Adjudication Study (TRIAS) Program. Am Heart J. 2009; 158: 527-532.e1, CrossRef.

Klomp M, Beijk MA, Varma C, Koolen JJ, Teiger E, Richardt G, et al. 1-Year outcome of TRIAS HR (TRI-stent Adjudication Study-High Risk of restenosis): A multicenter, randomized trial comparing genous endothelial progenitor cell capturing stents with drug-eluting stents. JACC Cardiovasc Interv. 2011; 4: 896-904, CrossRef.

Beijk MAM, Klomp M, Van Geloven N, Koch KT, Henriques JPS, Baan J, et al. Two-year follow-up of the genousTM endothelial progenitor cell capturing stent versus the taxus liberté stent in patients with de Novo coronary artery lesions with a high-risk of restenosis: A randomized, single-center, pilot study. Catheter Cardiovasc Interv. 2011; 78: 189-95, CrossRef.

Juliea PT, Kerkmeijer LS, Woudstra P, Kalkman D, Klomp M, Varma C, et al. Final 5-year results of the TRIAS-LR: a multi-centre, randomized trial comparing the genous endothelial progenitor cell capturing stent with bare metal stents in patients with low risk for restenosis. Eur Heart J. 2020; 41(Suppl 2): 2545, CrossRef.

Yamaji K, Kimura T. COMBO dual-therapy stent: non-inferior to drug-eluting stents or stepping back to bare metal stents? Eur Heart J. 2018; 39: 2469-71, CrossRef.

Saito S, Krucoff MW, Nakamura S, Mehran R, Maehara A, Al-Khalidi HR, et al. Japan-United States of America Harmonized Assessment by Randomized Multicentre Study of OrbusNEich’s Combo StEnt (Japan-USA HARMONEE) study: primary results of the pivotal registration study of combined endothelial progenitor cell capture and drug-eluting. Eur Heart J. 2018; 39: 2460-8, CrossRef.




DOI: https://doi.org/10.18585/inabj.v13i2.1570

Indexed by:

                 

                  

               

     

 

The Prodia Education and Research Institute